Drug Profile
Aprepitant intravenous - Heron Therapeutics
Alternative Names: APONVIE; Cinvanti; HTX-019Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Heron Therapeutics
- Class Anti-inflammatories; Antidepressants; Antiemetics; Antineoplastics; Antitussives; Antivirals; Fluorobenzenes; Ketones; Morpholines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Neurokinin 1 receptor antagonists; Peptide hydrolase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
- Phase II COVID 2019 infections
Most Recent Events
- 31 Dec 2023 Aprepitant intravenous has multiple patent protection in USA, Korea and Japan before December 2023
- 13 Mar 2023 Centers for Medicare & Medicaid Services (CMS) grants pass-through payment status for Aprepitant intravenous emulsion (APONVIE™)
- 06 Mar 2023 Launched for Postoperative nausea and vomiting (Prevention, In adults) in USA (IV)